Drug repurposing: a nexus of innovation, science, and potential

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The urgency of finding therapeutic solutions for emerging and existing health challenges has never been more pronounced. In the pursuit of this goal, the value of a strategy that makes use of existing resources is being recognized: drug repurposing or repositioning of compounds for new indications. Such approaches are employed against cancer, rheumatoid arthritis, multiple sclerosis, HIV/AIDS, and many other diseases. This Collection, aptly titled “Drug Repurposing”, includes research and perspectives from scientists at the forefront of this innovative field.

Related collections

Most cited references 9

Record: found
Abstract: found
Article: not found

Drug repurposing: progress, challenges and recommendations

Sudeep Pushpakom, Francesco Iorio, Patrick A. Eyers … (2018)

Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines. Various data-driven and experimental approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technological and regulatory challenges that need to be addressed. In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.

0 comments Cited 1075 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Pharos: Collating protein information to shed light on the druggable genome

Dac-Trung Nguyen, Stephen L. Mathias, Cristian Bologa … (2016)

The ‘druggable genome’ encompasses several protein families, but only a subset of targets within them have attracted significant research attention and thus have information about them publicly available. The Illuminating the Druggable Genome (IDG) program was initiated in 2014, has the goal of developing experimental techniques and a Knowledge Management Center (KMC) that would collect and organize information about protein targets from four families, representing the most common druggable targets with an emphasis on understudied proteins. Here, we describe two resources developed by the KMC: the Target Central Resource Database (TCRD) which collates many heterogeneous gene/protein datasets and Pharos (https://pharos.nih.gov), a multimodal web interface that presents the data from TCRD. We briefly describe the types and sources of data considered by the KMC and then highlight features of the Pharos interface designed to enable intuitive access to the IDG knowledgebase. The aim of Pharos is to encourage ‘serendipitous browsing’, whereby related, relevant information is made easily discoverable. We conclude by describing two use cases that highlight the utility of Pharos and TCRD.

0 comments Cited 121 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Natural Products as Platforms To Overcome Antibiotic Resistance.

Sean Rossiter, Madison H. Fletcher, William Wuest (2017)

Natural products have served as powerful therapeutics against pathogenic bacteria since the golden age of antibiotics of the mid-20th century. However, the increasing frequency of antibiotic-resistant infections clearly demonstrates that new antibiotics are critical for modern medicine. Because combinatorial approaches have not yielded effective drugs, we propose that the development of new antibiotics around proven natural scaffolds is the best short-term solution to the rising crisis of antibiotic resistance. We analyze herein synthetic approaches aiming to reengineer natural products into potent antibiotics. Furthermore, we discuss approaches in modulating quorum sensing and biofilm formation as a nonlethal method, as well as narrow-spectrum pathogen-specific antibiotics, which are of interest given new insights into the implications of disrupting the microbiome.

0 comments Cited 91 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Maria Cristina De Rosa:

ORCID: http://orcid.org/0000-0002-9611-2490

mariacristina.derosa@cnr.it

Rituraj Purohit: rituraj@ihbt.res.in

Alfonso T. García-Sosa:

ORCID: http://orcid.org/0000-0003-0542-4446

alfonsog@ut.ee

Journal

Journal ID (nlm-ta): Sci Rep

Journal ID (iso-abbrev): Sci Rep

Title: Scientific Reports

Publisher: Nature Publishing Group UK (London )

ISSN (Electronic): 2045-2322

Publication date (Electronic): 19 October 2023

Publication date PMC-release: 19 October 2023

Publication date Collection: 2023

Volume: 13

Electronic Location Identifier: 17887

Affiliations

[1 ]Institute of Chemical Sciences and Technologies “Giulio Natta” (SCITEC) – CNR, L.go F. Vito 1, 00168 Rome, Italy

[2 ]GRID grid.417640.0, ISNI 0000 0004 0500 553X, Structural Bioinformatics Lab, , CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), ; Palampur, HP 176061 India

[3 ]Academy of Scientific and Innovative Research (AcSIR), ( https://ror.org/053rcsq61) Ghaziabad, 201002 India

[4 ]Department of Molecular Technology, Institute of Chemistry, University of Tartu, ( https://ror.org/03z77qz90) Ravila 14a, 50411 Tartu, Estonia

Author information

Maria Cristina De Rosa http://orcid.org/0000-0002-9611-2490

Alfonso T. García-Sosa http://orcid.org/0000-0003-0542-4446

Article

Publisher ID: 44264

DOI: 10.1038/s41598-023-44264-7

PMC ID: 10587351

PubMed ID: 37857641

SO-VID: 7dd67842-d5c9-4965-8ef1-07d3f08c40d0

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Funding

Funded by: EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)

Award ID: HORIZON-HLTH-2021-ENVHLTH-03 PARC

Funded by: Eesti Teadusagentuur (Estonian Research Counci

Award ID: PRG1509

Award Recipient : Alfonso T. García-Sosa

Custom metadata

ScienceOpen disciplines: Uncategorized

Keywords: drug discovery and development,biotechnology

Data availability:

ScienceOpen disciplines: Uncategorized

Keywords: drug discovery and development, biotechnology

Drug repurposing: a nexus of innovation, science, and potential

Read this article at

Abstract

Related collections

Drug Repurposing Research Collection

Most cited references 9

Drug repurposing: progress, challenges and recommendations

Pharos: Collating protein information to shed light on the druggable genome

Natural Products as Platforms To Overcome Antibiotic Resistance.

Author and article information

Contributors

Journal

Affiliations

Author information

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 253

Cited by 1

Most referenced authors 171